Gilead of­fers a glimpse at hard da­ta to back up its $600M in­vest­ment in Nim­bus’ NASH drug

Gilead $GILD paid $600 mil­lion in fast cash to Nim­bus to ac­quire rights to its ear­ly-stage NASH drug. And to­day it of­fered an­oth­er rea­son why, while al­so demon­strat­ing just how speedy this big biotech’s R&D squad can be when they feel like they’re on to some­thing big.

Their drug, GS-0976, an in­hibitor of Acetyl-CoA car­boxy­lase, slashed lev­els of liv­er fat — the key cul­prit in NASH — by a me­di­an 43% in 10 pa­tients in an open-la­bel proof-of-con­cept study cov­er­ing 12 weeks of ther­a­py. There was a me­di­an de­crease of 29 per­cent in he­pat­ic DNL.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER